Cited by 150Mesenchymal stem cell researchMultiple Sclerosis Research StudiesExtracellular vesicles in disease

Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases

Open access
Staff, Nathan P., Jones, David T., Singer, Wolfgang·2019·Mayo Clinic Proceedings

Abstract

Mesenchymal stromal cells are multipotent cells that are being used to treat a variety of medical conditions. Over the past decade, there has been considerable excitement about using MSCs to treat neurodegenerative diseases, which are diseases that are typically fatal and without other robust therapies. In this review, we discuss the proposed MSC mechanisms of action in neurodegenerative diseases, which include growth factor secretion, exosome secretion, and attenuation of neuroinflammation. We then provide a summary of preclinical and early clinical work on MSC therapies in amyotrophic lateral sclerosis, multiple system atrophy, Parkinson disease, and Alzheimer disease. Continued rigorous and controlled studies of MSC therapies will be critical in order to establish efficacy and protect patients from possible untoward effects.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.mayocp.2019.01.001

Cites

193 of 193 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Mesenchymal stem cell transplantation for Parkinson's disease can significantly improve the daily activities and motor functions of Parkinson's disease patients without side effects, as well as being safe and reliable.

    “Meanwhile, mesenchymal stem cell transplantation for Parkinson’s disease can significantly improve the daily activities and motor functions of Parkinson’s disease patients without side effects, as well as being safe and reliable.363,364”

    From Inflammation and aging: signaling pathways and intervention therapies (2023) · cites this paper as [364]

    The Parkinson’s disease section reports preliminary human studies in which some patients improved on Parkinson’s rating scales; it also says the procedure in the seven-patient study was well tolerated. It does not establish a significant improvement in daily activities and motor function across patients, an absence of side effects, or that transplantation is reliably safe. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

2 retracted

Flagged first, then by citations

Research works printed but not linked: 2

  1. [91]Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol. 2010; 67: 1187– 1194. 20937945 PMC3036569
  2. [135]Ochs G, Penn RD, York M, A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. 2000; 1: 201– 206. 11464953

Cited by

Sorted by citations

Authors
Staff, N. P., Jones, D. T., & Singer, W.
Affiliations
Mayo Clinic (US)
Corresponding author
Staff, Nathan P.
Venue
Mayo Clinic Proceedings
Publisher
Elsevier BV
Published
2019-05
Volume
94
Issue
5
Pages
892-905
ISSN
0025-6196 (ISSN-L)
OpenAlex
W2943517835
Cited by
150
References
193
Citations by year
2026: 10 · 2025: 7 · 2024: 18 · 2023: 38 · 2022: 26 · 2021: 26 · 2020: 23 · 2019: 2
FWCI
2.34
Type
journal article
Language
en
Open access
Locations
  • Mayo Clinic Proceedings (acceptedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • U.S. Food and Drug Administration (R01 FD004789)
  • National Cancer Institute (R01CA211887)
  • National Institute of Neurological Disorders and Stroke (U54NS065736, R01NS092625)
Topics
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
Keywords
mesenchymal stem cells, neurodegenerative diseases, amyotrophic lateral sclerosis, multiple system atrophy, Parkinson's disease, Alzheimer's disease, growth factor secretion, exosomes, neuroinflammation
MeSH terms
Alzheimer Disease, Amyotrophic Lateral Sclerosis, Animals, Clinical Trials as Topic, Humans, Parkinson Disease, Multiple System Atrophy, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review